Migraine | Treatment Algorithms: Claims Data Analysis | Migraine Prophylaxis | US | 2025

Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns focuses specifically on the prophylactic treatment of migraine, aimed at preemptively reducing the frequency, severity, and duration of future migraine attacks and, in turn, reducing patients’ level of disability and potentially increasing the responsiveness of breakthrough migraine attacks to acute treatment. Although generic AEDs, antidepressants, and beta blockers dominate the first three lines of therapy, our report provides insight into both the market-leading classes and the uptake of brands, such as CGRP monoclonal antibodies and the CGRP-targeted oral therapy Qulipta (AbbVie). We do not include Pfizer’s Nurtec ODT in our main analysis as we cannot easily parse out the acute use of the drug from its prophylactic use.

Questions answered

• What patient shares do key therapies and brands garner in the treatment of prophylactically naive migraine patients? What are the quarterly trends in prescribing of prophylactic therapies among recently treated and prophylactically naive migraine patients? ·
• How have CGRP-targeted therapies been integrated into the prophylactic treatment algorithm, and what is their source of business? What switching patterns exist between different MAbs and between MAbs and Qulipta?
• What percentage of prophylactically naive migraine patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of prophylactic therapy within two years of diagnosis?
• What percentage of migraine patients are treated with monotherapy versus combination prophylactic therapy? What are the most commonly used combinations?
• What is the product-level compliance and persistency rates for prophylactic therapies among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy
• Evaluate your brand share against competitors
• Accurately assess your source of business
• Quantify opportunities at different stages of the treatment algorithm

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Key drugs covered:

Aimovig, Emgality, Ajovy, Vyepti, Qulipta, Botox, topiramate XR, Trokendi XR, amitriptyline, propranolol

Key analyses:

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.